AstraZeneca: diabetes drug shows cardiovascular safety.

(CercleFinance.com) - AstraZeneca said on Tuesday that a late-stage trial has showed evidence of the cardiovascular safety profile of Bydureon across a wide range of patients with type-2 diabetes.


The firm today unveiled top-line results from a Phase IIIb/IV trial, comparing the effect of once-weekly Bydureon versus placebo, when added to usual type-2 diabetes care, on the risk of non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes.

The trial met its primary safety objective, with fewer cardiovascular events observed in the Bydureon arm of the trial.

However, the efficacy objective of a superior reduction did not reach statistical significance, AstraZeneca said.

Copyright (c) 2017 CercleFinance.com. All rights reserved.